Combining Brexpiprazole (Rexulti) and Risperidone in Elderly Dementia Patients
No, an elderly patient with dementia should not be prescribed both brexpiprazole and risperidone simultaneously. This combination is inappropriate and potentially dangerous due to additive risks without evidence of benefit.
Primary Rationale
Avoid combining multiple antipsychotics in dementia patients because:
- Both drugs carry FDA black box warnings for increased mortality in elderly patients with dementia-related psychosis 1, 2
- Risperidone increases death risk 1.6-1.7 times compared to placebo in this population 1
- Both medications significantly increase cerebrovascular adverse events (stroke, TIA) in elderly dementia patients 1
- The 2019 AGS Beers Criteria explicitly warns against concurrent use of three or more CNS agents (including multiple antipsychotics), which increases fall risk 3
Why This Combination Makes No Clinical Sense
There is no evidence supporting dual antipsychotic therapy in dementia, and the practice violates fundamental prescribing principles 4:
- If one antipsychotic is ineffective, switching (not adding) is the appropriate strategy
- Combining two antipsychotics compounds side effects including extrapyramidal symptoms, sedation, metabolic effects, and cardiovascular risks 1, 2
- Neither brexpiprazole nor risperidone is FDA-approved for dementia-related psychosis; both are used off-label with significant safety concerns 1, 2, 5
Appropriate Antipsychotic Use in Dementia
If antipsychotic treatment is deemed necessary (only for dangerous agitation or psychosis after non-pharmacological interventions fail) 4:
- Use monotherapy only - select a single agent based on the clinical presentation 4
- For agitated dementia with delusions: Risperidone 0.5-2.0 mg/day is first-line, with quetiapine 50-150 mg/day or olanzapine 5.0-7.5 mg/day as alternatives 6
- For agitation in Alzheimer's disease: Brexpiprazole 2-3 mg/day is the only FDA-approved option for this specific indication (approved 2023), though it takes 6-12 weeks to show effect 7, 8
- Duration should be limited: attempt to taper within 3-6 months to determine the lowest effective maintenance dose for agitated dementia 6
Critical Safety Monitoring
When using any single antipsychotic in elderly dementia patients 1, 2:
- Monitor for cerebrovascular events (stroke symptoms, focal neurological changes)
- Assess for extrapyramidal symptoms and tardive dyskinesia risk
- Watch for increased fall risk and fractures
- Monitor cognition - antipsychotics can worsen cognitive function
- Evaluate mortality risk factors, particularly cardiovascular and infectious complications
- Reassess need for continued treatment regularly
The Bottom Line
Polypharmacy with multiple antipsychotics multiplies risks without evidence of benefit 4, 3. If the current antipsychotic is ineffective, the appropriate approach is to switch to an alternative agent, not to add a second one. The modest benefits of antipsychotics in dementia (effect sizes are small across all agents) 4, 9 do not justify the compounded risks of dual therapy, which include significantly increased mortality, stroke risk, falls, and cognitive decline.